Highlights

  • Ethics approval has been secured for Goulburn Valley Hospital in Victoria, expanding the CERE-CALM trial network beyond New South Wales for the first time.
  • The first patient was successfully enrolled in October 2026 at Cognivus Research, with first patient treatment expected in the coming weeks.
  • Training is now complete at John Hunter Medical Research Institute and is scheduled to begin at St Vincent's Hospital Sydney in December 2026.
  • CERE-CALM targets 66 participants and is a fully funded, randomised, double-blind, sham-controlled Phase 2 trial, with completion anticipated in the first half of CY2028.

Ceretas Limited (ASX:CTS) has announced that St Vincent's Hospital Sydney's Human Research Ethics Committee has approved the inclusion of Goulburn Valley Hospital in Victoria as an additional clinical site for the Phase 2 CERE-CALM clinical trial. This marks the first expansion of the trial beyond New South Wales, broadening the company's Australian clinical trial network and increasing access to eligible patients. Ceretas is developing a portable, non-invasive therapeutic ultrasound platform targeting Alzheimer's disease and other neurodegenerative conditions, with its technology based on more than a decade of research at the University of Queensland and the Queensland Brain Institute.

Trial Design and Current Enrolment Status

CERE-CALM is a fully funded, randomised, double-blind, sham-controlled Phase 2 trial evaluating low-intensity focused ultrasound neuromodulation as a potential treatment for behavioural and psychological symptoms of dementia (BPSD) in patients with probable Alzheimer's disease. Participants aged 50 and over receive six treatments over twelve weeks — four weekly sessions followed by two monthly sessions. The primary endpoint is the change in neuropsychiatric symptom burden from baseline to week six, measured using the Neuropsychiatric Inventory total score, comparing active treatment with sham control. The trial targets 66 participants (minimum 60), randomised on a two-to-one basis between active treatment and sham.

Patient recruitment commenced at Cognivus Research in October 2026, with the first patient successfully enrolled. The addition of Goulburn Valley Hospital expands recruitment capacity, while further Australian sites are also being considered. Training has been completed at John Hunter Medical Research Institute and is scheduled to begin at St Vincent's Hospital Sydney in December 2026. The company expects first patient treatments to commence in the coming weeks.

The Technology and Clinical Rationale

The Ceretas device directs low-intensity focused ultrasound through the skull to act on brain tissue via two mechanisms: neuromodulation, targeting neural circuits involved in memory, cognition, and behavioural symptoms of dementia; and blood-brain barrier opening, which may facilitate clearance of disease-associated proteins and enhance delivery of therapeutic agents to the brain. The technology is non-invasive and portable, distinguishing it from more complex or surgically implanted neurological interventions.

In 2024, researchers at the Queensland Brain Institute completed a first-in-human Phase 1 trial of low-intensity focused ultrasound neuromodulation in twelve Alzheimer's participants, finding the treatment to be safe and well tolerated, with encouraging early signals of benefit for behavioural symptoms. The results were published in Brain Communications in December 2025. This Phase 1 evidence base, together with the mechanistic rationale, supports the Phase 2 evaluation in CERE-CALM. The Queensland Brain Institute is also separately running the AGIFUS Phase 2 trial evaluating the same technology in Alzheimer's-related agitation, funded independently by Queensland Health.

Funding Position and Regulatory Progress

CERE-CALM is described as a fully funded trial, which reduces the near-term Capital risk associated with programme execution. The expansion into Victoria reflects the company's strategy of building a multi-site Australian network to support patient recruitment and to broaden the geographic diversity of the participant population. Trial completion is anticipated in the first half of CY2028, following a twelve-week treatment period per participant and the enrolment of the target sixty-six participants.

Ceretas is a clinical-stage medical technology company, and the successful execution of CERE-CALM represents the next significant milestone in its clinical development programme. The company is pursuing both neuromodulation and blood-brain barrier opening as therapeutic mechanisms, with the CERE-CALM trial designed to generate controlled evidence on the efficacy and safety of the approach in a defined Alzheimer's patient population with behavioural and psychological symptoms.

Key Insights

The Victoria site expansion is a material step in building recruitment capacity, as the CERE-CALM trial's success depends on timely enrolment of its minimum sixty-patient target within the planned timeframe.

The imminent commencement of patient treatments marks the transition from preparation to clinical execution, with treatment data generation expected to begin in the near term across multiple Australian sites.

The parallel AGIFUS trial run by the Queensland Brain Institute using the same technology provides an additional evidence stream that could inform the broader clinical development programme without direct cost to Ceretas.